Advertisement
News
Subscribe to MDT Magazine News

EV group introduces new EVG610 mask and bond aligner optimized for greater cost and process flexibility

July 7, 2010 10:39 am | by I-Micronews | Comments

New system provides World-class alignment technology at an affordable cost

MTuitive brings OpNote tech to UMass Medical

July 7, 2010 10:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Centerville-based mTuitive Inc. has a new customer in UMass Memorial Medical Center's Division of Neurosurgery, which plans to use the company's OpNote technology to track surgical findings.

Alnylam launches drug trial to treat rare disease

July 7, 2010 10:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Alnylam Pharmaceuticals Inc. has launched a Phase 1 trial for a drug candidate targeting a rare disease known as ATTR. Investors and analysts are taking notice because it is one of just a handful of RNAi human trials ongoing.

TOPICS:
Advertisement

Cancer deaths continue to drop

July 7, 2010 10:34 am | by EurekAlert | Comments

(American Cancer Society) The continued drop in overall cancer mortality rates over the last 20 years has averted more than 767,000 cancer deaths according to a new report from the American Cancer Society.

TOPICS:

Summary Information for: Implantable Miniature Telescope?

July 7, 2010 10:31 am | by U.S. Food & Drug Administration | Comments

Labeling, Approval Order, and Summary of Safety and Effectiveness for Implantable Miniature Telescope? (P050034).

TOPICS:

510(k) Final Decisions - June 2010(2)

July 7, 2010 10:31 am | by U.S. Food & Drug Administration | Comments

Page Last Updated: 07/07/2010 Note: If you need help accessing information in different file formats, see Instructions for Downlo

TOPICS:

510(k) Final Decisions - June 2010

July 7, 2010 10:30 am | Comments

Page Last Updated: 07/07/2010 Note: If you need help accessing information in different file formats, see Instructions for Downlo

Synageva gains orphan drug status for enzyme therapy

July 7, 2010 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Synageva BioPharma Corp. announced today that the U.S. Food and Drug Administration has granted the company orphan drug designation for its enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency.

Advertisement

Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed's Oral Insulin Capsules

July 7, 2010 8:35 am | by Bio-Medicine.Org | Comments

JERUSALEM, Israel , July 7, 2010 /- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement (MSA) with sanofi-aventis. According to the MSA, sanofi-aventis will...

TOPICS:

Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina

July 7, 2010 8:35 am | by Bio-Medicine.Org | Comments

NEW YORK , July 7 /- Reportlinker.com announces that a new market research report is available in its catalogue: Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina http://www.reportlinker.com/p0186217/Stakeholder-Opinions-Vaccines-in...

TOPICS:

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity

July 7, 2010 8:34 am | by Bio-Medicine.Org | Comments

NEW YORK , July 7 /- Reportlinker.com announces that a new market research report is available in its catalogue: Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity http://www.reportlinker.com/p0...

TOPICS:

Renhuang Begins Trading on NYSE Amex

July 7, 2010 8:34 am | by Bio-Medicine.Org | Comments

HARBIN, China , July 7 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP ) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that,...

TOPICS:

Ethicon, Inc. Expands Hemostasis Product Portfolio with Approval of the Company's First Synthetic Internal Use Sealant

July 7, 2010 8:33 am | by Bio-Medicine.Org | Comments

SOMERVILLE, N.J. , July 7 /- Ethicon, Inc., a worldwide leader in surgical care, announced today the introduction of ETHICON™ OMNEX™ Surgical Sealant, ETHICON™ Biosurgery's first synthetic sealant designed to achieve adjunctive hemostasis (stoppage of bleeding) in...

TOPICS:

Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas

July 7, 2010 8:33 am | by Bio-Medicine.Org | Comments

CINCINNATI , July 7 /PRNewswire-USNewswire/ -- Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according...

TOPICS:

Genetically reprogrammed HSV given systemically shrinks distant sarcomas

July 7, 2010 7:37 am | by EurekAlert | Comments

(Cincinnati Children's Hospital Medical Center) Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice -- still an elusive goal when treating humans with cancer,...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading